WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

"A COMPRHENSIVE REVIEW ON CHALLENGES AND ADVANCEMENT IN TRANSDERMAL DRUG DELIVERY SYSTEM"

Ms. Samruddhi Kamlakar Patil , (Dr.) Sonali Uppalwar , Mr. Abhishek Kumar Sen, Mr. Zeeshan Mohammad Khan

8806205305, Final Year B. Pharmacy, Ideal Institute of Pharmacy, Posheri, 421303. Email id: samruddhip03@gmail.com
Principal, Ideal Institute of Pharmacy, Posheri, 421303.
Vice-Principal, Ideal Institute of Pharmacy, Posheri, 421303.
Class Teacher, Ideal Institute of Pharmacy, Posheri, 421303.

ABSTRACT :

Transdermal Drug Delivery Systems (TDDS) represent a novel approach in the pharmaceutical domain, providing an effective alternative to conventional drug delivery methods. These systems facilitate the controlled release of therapeutic agents through the skin into systemic circulation, overcoming challenges associated with oral and injectable drug administration. TDDS eliminates first-pass metabolism, reduces gastrointestinal side effects, and improves patient compliance by offering non-invasive, painless drug administration with sustained plasma levels.

The design of transdermal patches incorporates key components, including drug reservoirs, polymer matrices, permeation enhancers, and adhesives, which collectively determine the effectiveness and efficiency of drug delivery. Advances in technologies such as microneedles, iontophoresis, and nanotechnology have further expanded the range of drugs deliverable via TDDS, addressing challenges of permeability and molecule size.

Applications of TDDS are vast, spanning nicotine patches for smoking cessation, hormone replacement therapies, pain management, and chronic condition treatments. However, the approach faces limitations such as skin irritation, restricted drug types, and the need for continuous innovation in polymer science and enhancement strategies.

This review explores the anatomical and physiological basis of transdermal drug delivery, the mechanisms of permeation, the design and evaluation of TDDS, and its medical applications. Future directions in this field are focused on overcoming existing challenges to enhance the scope and efficiency of TDDS as a next-generation drug delivery system.

Key words:- gastrointestinal, nanotechnology, administration, patches.

Introduction :

Transdermal Drug Delivery Systems (TDDS) are innovative pharmaceutical technologies designed to deliver drugs through the skin into systemic circulation, offering significant advantages over conventional delivery routes. By bypassing the gastrointestinal tract and avoiding first-pass metabolism, TDDS improves bioavailability and minimizes side effects associated with oral and injectable drug administration [1]. The method also provides a controlled and sustained release of medication, enhancing patient compliance, especially for drugs requiring frequent dosing [2].

The history of TDDS dates back to the late 20th century, with the FDA's approval of the first transdermal patch in 1979 for scopolamine to treat motion sickness [3]. Over the decades, advances in materials science and pharmaceutical technology have diversified the application of TDDS, including patches for nicotine replacement therapy, pain management with fentanyl, and hormone replacement therapy using oestradiol [4].

TDDS relies on the unique anatomy and physiology of the skin, which acts as both a barrier and a conduit for drug delivery. The stratum corneum, the outermost layer, is the primary barrier, requiring drugs to possess specific physicochemical properties such as low molecular weight and balanced lipophilicity to permeate effectively [5]. Despite these constraints, advances in enhancers like iontophoresis and microneedles have significantly broadened the spectrum of deliverable drugs [6].

This review aims to explore the underlying mechanisms, components, types, and advancements in TDDS, with an emphasis on its medical applications. By addressing existing challenges, such as skin irritation and limited drug permeability, TDDS continues to evolve as a next-generation drug delivery platform.

Advantages and Disadvantages :

Advantages

1. Avoids First-Pass Metabolism:
   TDDS bypasses the liver's first-pass effect, ensuring higher bioavailability of drugs .
2. Non-Invasive Delivery:
   As a painless alternative to injections, TDDS improves patient compliance, especially in long-term therapies .
3. Sustained and Controlled Release:
   It provides controlled, steady drug release, maintaining consistent plasma levels and reducing dosing frequency .
4. Improved Patient Compliance:
   With reduced dosing frequency and ease of use, TDDS enhances adherence, especially for chronic conditions .
5. Reduction of Side Effects:
   Unlike oral formulations, TDDS minimizes gastrointestinal irritation and systemic side effects by preventing drug concentration spikes .
6. Suitable for Patients with Swallowing Difficulties:
   TDDS is an excellent option for patients unable to take oral medication due to dysphagia nausea or vomiting.
7. Reversible Therapy:
   Therapy can be discontinued quickly by removing the patch, offering better control in case of adverse effects .

Disadvantages

1. Limited to Potent Drugs:
   Only drugs with low molecular weight, high potency, and balanced lipophilicity are suitable due to skin permeability constraints .
2. Risk of Skin Irritation and Allergies:
   Prolonged use or adhesive components in patches can cause skin irritation, contact dermatitis, or hypersensitivity reactions .
3. Variable Absorption Rates:
   Skin conditions (hydration, thickness, and damage) and environmental factors may affect drug absorption, leading to inconsistent dosing .
4. Unsuitability for Large Molecules:
   Macromolecules like peptides and proteins face significant barriers to penetration, limiting TDDS applicability .
5. Application Issues:
   Improper patch placement, detachment, or interaction with external elements like clothing can compromise drug delivery efficacy .
6. High Production Costs:
   Development and manufacturing of TDDS involve advanced materials and technologies, leading to higher costs compared to conventional dosage forms .
7. Limited Drug Loading Capacity:
   Due to size and skin absorption constraints, patches cannot accommodate high drug doses or molecules requiring large plasma concentrations

Anatomy and Physiology of the Skin :

The skin is the largest organ of the human body, covering an average surface area of approximately 2 square meters. It serves as a critical barrier against external environmental factors and plays a vital role in maintaining homeostasis . The skin is composed of three distinct layers: the epidermis, dermis, and hypodermis, each contributing to its protective and regulatory functions.



1. Epidermis

The epidermis is the outermost layer of the skin, characterized by a stratified squamous epithelium that lacks blood vessels. It is further divided into five sub-layers: the stratum corneum, stratum lucidum, stratum granulosum, stratum spinosum, and stratum Basile.

- **Stratum Corneum (Horny Layer):**
  The stratum corneum, approximately 10–20 μm thick, is the principal barrier to drug penetration in transdermal drug delivery systems (TDDS). It consists of keratinized, dead cells embedded in a lipid matrix. These lipids, organized in bilayers, restrict the passage of water-soluble molecules but allow lipophilic substances to permeate to some extent .
- **Viable Epidermis:**
  Beneath the stratum corneum, the viable epidermis is responsible for the continuous regeneration of skin cells. It contains living keratinocytes that undergo mitosis and differentiate as they migrate upwards to replace cells in the stratum corneum .

2. Dermis

The dermis lies beneath the epidermis and is 3–5 mm thick. It is primarily composed of connective tissue containing collagen and elastin fibers, blood vessels, lymphatic vessels, and nerve endings.

- **Capillary Network:**
  The capillaries extend close to the epidermis and serve as a sink for drug molecules that permeate through the skin. This gradient helps drive drugs from the epidermis into systemic circulation .
- **Role in Temperature Regulation and Sensory Function:**
  The dermis contains thermoregulatory structures such as sweat glands and sensory receptors that respond to external stimuli, making it integral to maintaining homeostasis .

3. Hypodermis

The hypodermis, or subcutaneous tissue, is the innermost layer of the skin. It consists predominantly of adipose tissue, which provides insulation, energy storage, and cushioning for underlying muscles and bones.

- **Supportive Role in Drug Delivery:**
  The hypodermis facilitates systemic absorption of drugs that successfully permeate the upper layers of the skin. Its vascular network is essential for transporting drugs into the bloodstream .

Mechanisms of Drug Permeation

Transdermal drug delivery involves the passage of therapeutic agents across the skin layers into systemic circulation. The primary challenge is overcoming the barrier properties of the stratum corneum, the outermost layer of the skin. Drug permeation is a multistep process influenced by the physicochemical properties of the drug and the skin's structure .

1. Steps of Drug Permeation

- Sorption by the Stratum Corneum:
  The drug is absorbed by the stratum corneum, which acts as the rate-limiting barrier.
  This absorption depends on the drug's ability to partition into the lipid bilayers of the
- stratum corneum .
  Penetration through the Viable Epidermis:
  Once the drug crosses the stratum corneum, it diffuses through the hydrophilic layers of the viable epidermis, including keratinocytes and interstitial fluid .
- Uptake by Dermal Capillaries
  After traversing the dermis, the drug enters the capillary network, where it is absorbed into systemic circulation .

2. Pathways of Drug Permeation

Drugs can traverse the skin using the following pathways:

- **Transcellular Pathway:**
  The drug moves through keratinized cells of the stratum corneum. This requires partitioning into and out of hydrophilic and lipophilic domains, making it ideal for small, moderately lipophilic molecules .
- **Intercellular Pathway:**
  The drug diffuses through lipid bilayers between corneocytes. Lipophilic drugs favour this route due to the lipid-rich environment .
- **Appendageal Pathway:**
  This involves transport through hair follicles and sweat glands. Although limited in surface area, this pathway is significant for hydrophilic and large molecules, including proteins .

3. Factors Influencing Permeation

i. Drug Properties:
   - Molecular Size: Drugs with a molecular weight under 500 Da permeate more effectively .
   - Lipophilicity: Drugs with balanced lipophilic and hydrophilic characteristics have higher permeability.

ii. Skin Conditions:
   - Hydration: Hydrated skin enhances drug absorption by disrupting the lipid matrix.
   - Temperature and pH: Increased temperature improves diffusion rates, while pH affects drug ionization, influencing permeability .

iii. Enhancement Techniques:

- Chemical Enhancers: Substances like ethanol and propylene glycol disrupt the lipid bilayers, improving permeation.
- Physical Techniques: Methods like iontophoresis, microneedles, and ultrasound create pathways or use external forces to enhance delivery .

4. Kinetics of Drug Permeation

The rate of drug permeation can be expressed mathematically:

dQdt=Ps·(Cd−Cr)\frac{dQ}{dt} = P_s \cdot (C_d - C_r)dtdQ =Ps ·(Cd −Cr)

Where:

- dQdt\frac{dQ}{dt}dtdQ : Rate of drug permeation
- PsP_sPs : Permeability coefficient of the skin
- CdC_dCd : Drug concentration in the donor compartment
- CrC_rCr : Drug concentration in the receptor compartment [11].

For effective transdermal delivery, Cd≫CrC_d \gg C_rCd ≫Cr , ensuring a consistent concentration gradient across the skin [12].

Components of Transdermal Patches :

Transdermal patches are sophisticated drug delivery systems that rely on their structural components to ensure controlled drug release and effective permeation through the skin. The performance of a patch is determined by the design and selection of its key components, each contributing to the stability, permeability, and drug-release profile .

1. Drug Reservoir

The drug reservoir holds the active pharmaceutical ingredient (API) in a suitable form, such as a solution, suspension, or gel. The concentration of the drug in the reservoir influences the release rate, which is often designed to follow zero-order kinetics .

- Requirements: The drug should have a molecular weight under 500 Da, low melting point, and sufficient potency for effective transdermal delivery .

2. Polymer Matrix

The polymer matrix is the backbone of the patch, controlling the release rate of the drug. It ensures consistent drug diffusion and structural stability.

- Criteria for Selection:
  - Non-toxic and biocompatible.
  - Chemically and physically stable.
  - Affordable and easy to manufacture .
- Types of Polymers:
  - Natural Polymers: Cellulose derivatives, starch, gelatin.
  - Synthetic Polymers: Polyvinyl alcohol, polyethylene, silicone elastomers.

3. Permeation Enhancers

Permeation enhancers are substances that temporarily disrupt the stratum corneum, allowing the drug to penetrate more effectively.

- Types of Enhancers:
  - Solvents: Ethanol, propylene glycol.
  - Surfactants: Sodium lauryl sulphates, bile salts.
  - Miscellaneous Chemicals: Urea, calcium thioglycolate .
- Mechanism of Action: They alter lipid bilayer fluidity, interact with keratin, or increase skin hydration to improve permeability.

4. Adhesive Layer

The adhesive layer ensures the patch adheres firmly to the skin while allowing drug diffusion. It must be non-irritant, skin-friendly, and compatible with the drug and other components.

- Types of Adhesives:
  - Acrylates, silicones, and polyisobutylene.
- Key Properties:
  - High tackiness to prevent patch displacement.
  - Easily removable without leaving residues .

5. Backing Layer

The backing layer provides structural support and prevents the drug from evaporating or interacting with the external environment.

- Material Requirements:
  - Impermeable to water and drugs.
  - Flexible, durable, and chemically inert.
- Common Materials: Polyester, polyethylene, and aluminium films .

6. Release Liner

The release liner is a protective layer removed before application. It prevents contamination and ensures stability during storage.

- Material Composition: Polyethylene or fluoropolymer-coated materials, which ensure easy peeling without damaging the adhesive layer .

7. Other Additives

Additional excipients may include plasticizers to enhance flexibility and stability, or stabilizers to prevent drug degradation.

Types of Transdermal Patches

Transdermal patches are designed to deliver drugs across the skin using different configurations and mechanisms. These variations are optimized based on the nature of the drug, desired release profile, and therapeutic application . The primary types of transdermal patches include the following:

1. Single-Layer Drug-in-Adhesive Patches

In this system, the drug is directly incorporated into the adhesive layer. This layer performs dual functions: adhering the patch to the skin and releasing the drug.

- Advantages:
  - Simplified design with fewer layers.
  - Uniform drug distribution.
- Disadvantages:
  - Limited to drugs with specific release characteristics.
- Applications: Hormonal replacement therapies and nicotine patches .

2. Multi-Layer Drug-in-Adhesive Patches

Similar to the single-layer system but includes multiple adhesive layers, each with different drug concentrations.

- Features:
  - Allows sequential drug release.
  - Often separated by a release-controlling membrane.
- Applications: Used for conditions requiring a sustained release of multiple drugs .

3. Reservoir Patches

The reservoir system includes a separate compartment containing the drug in liquid or gel form. A rate-controlling membrane lies between the reservoir and the adhesive layer, ensuring zero-order drug release.

- Advantages:
  - Precise control over drug release rates.
  - Suitable for potent drugs.
- Disadvantages:
  - Risk of dose dumping if the membrane ruptures.
- Applications: Fentanyl patches for chronic pain management .

4. Matrix Patches

The drug is dispersed within a polymeric matrix layer, which controls the drug release rate. The adhesive layer surrounds or overlaps the matrix.

- Advantages:
  - Simplified manufacturing compared to reservoir systems.
  - No risk of dose dumping.
- Disadvantages:
  - Limited control over the release profile.
- Applications: Nitroglycerin patches for angina .

5. Vapor Patches

These patches release active ingredients in the form of vapours instead of transdermal drug absorption.

- Features:
  - Used for decongestion or aromatherapy.
  - Duration of action is typically short.
- Applications: Decongestants and sleep-inducing patches .

Comparison of Patch Types

Type	Drug Form	Release Mechanism	Risk of Dose Dumping	Example Applications
Single-Layer	In adhesive	Diffusion from adhesive	Low	Nicotine, Oestradiol patches
Multi-Layer	In adhesive layers	Sequential release via layers	Low	Multi-drug therapies
Reservoir	Liquid/Gel	Zero-order through membrane	High	Fentanyl, scopolamine patches
Matrix	Polymeric matrix	Diffusion through matrix	Very low	Nitroglycerin, clonidine patches
Vapor	Active vapours	Evaporation	None	Aromatherapy, decongestants

Applications of Transdermal Drug Delivery Systems

Transdermal Drug Delivery Systems (TDDS) have revolutionized the way medications are administered, offering significant advantages, such as bypassing first-pass metabolism, providing sustained and controlled release, and improving patient compliance. By utilizing the skin as a pathway for drug absorption, these systems are particularly beneficial for patients requiring continuous medication over long periods. Below is a more detailed exploration of the key applications of TDDS.

1. Pain Management

One of the most established uses of TDDS is in the management of chronic pain. The ability to provide long-lasting, controlled analgesia with a single patch application is highly beneficial for patients suffering from severe, persistent pain, especially those with cancer or other conditions that require continuous opioid therapy.

- Example: Fentanyl patches are commonly used for opioid-based pain management. These patches release fentanyl, a potent synthetic opioid, steadily over a period of up to 72 hours, ensuring that the patient receives continuous pain relief without the peaks and troughs typically associated with oral medications. This controlled release also helps reduce the risk of drug dependence and abuse.
- Other Applications: Lidocaine patches are used to manage localized pain, such as post-herpetic neuralgia (pain following shingles). These patches deliver lidocaine directly to the site of pain, numbing the area and providing targeted relief. Additionally, ketoprofen patches, used for inflammatory pain, release the anti-inflammatory drug at the site of injury, offering effective relief with minimal systemic side effects.

2. Hormonal Replacement Therapy (HRT)

Transdermal patches are a common choice for delivering hormones in conditions that require hormone replacement, such as menopause or testosterone deficiency. These systems offer the advantage of steady hormone levels without the gastrointestinal side effects often associated with oral administration.

- Example: Estradiol patches are widely used in hormone replacement therapy (HRT) for women experiencing menopause. These patches deliver estradiol, the primary form of estrogen, over several days, helping alleviate symptoms such as hot flashes, night sweats, and mood swings. Additionally, they can reduce the risk of osteoporosis, as estrogen plays a critical role in bone health.
- Other Applications: Testosterone patches are used in men with low testosterone levels due to conditions like hypogonadism. These patches provide a steady release of testosterone, addressing symptoms such as fatigue, decreased libido, and muscle weakness.

3. Smoking Cessation

Nicotine replacement therapy (NRT) is another area where TDDS has proven to be particularly effective. Nicotine patches offer a controlled release of nicotine, helping to reduce withdrawal symptoms and cravings associated with smoking cessation.

- Example: Nicotine patches are available in different strengths to provide a gradual reduction of nicotine dependence. The patches deliver nicotine at a constant rate throughout the day, helping to prevent the peaks in blood nicotine levels that are experienced with smoking, thereby making the process of quitting smoking more manageable.

4. Motion Sickness and Nausea

TDDS are also useful for the prevention and treatment of motion sickness and nausea, offering a non-invasive way to manage these conditions over long durations. The patches deliver medication in a controlled manner, ensuring consistent effectiveness.

- Example: Scopolamine patches are often used for the prevention of motion sickness, particularly during long journeys or surgeries. The patches are typically applied behind the ear and deliver scopolamine transdermally over a period of up to 72 hours, reducing nausea and vomiting associated with motion sickness or anaesthesia.

5. Cardiovascular Conditions

Transdermal patches are used for the treatment of various cardiovascular conditions, providing controlled delivery of drugs that help manage heart disease, hypertension, and related disorders.

- Example: Nitroglycerin patches are used to manage angina pectoris by dilating blood vessels and improving blood flow to the heart. These patches release nitroglycerin steadily over a 24-hour period, preventing the chest pain associated with reduced blood flow.
- Other Applications: Clonidine patches are used in the management of hypertension and to control heart rate, as clonidine helps lower blood pressure and manage withdrawal symptoms from certain drugs.

6. Dermatological Conditions

TDDS are increasingly used in dermatology for both localized and systemic treatment of various skin conditions. By delivering drugs directly to the site of action, these patches can offer more effective treatment with fewer systemic side effects.

- Example: Hydrocortisone patches are used for inflammatory skin conditions like eczema or psoriasis. These patches deliver corticosteroids directly to the skin, reducing inflammation and promoting healing.
- Other Applications: Patches containing diclofenac or ketoprofen can be used for the treatment of musculoskeletal pain, providing localized anti-inflammatory effects with minimal systemic exposure.

Conclusion :

Transdermal Drug Delivery Systems (TDDS) have emerged as a transformative approach to drug administration, providing a versatile platform for the controlled, sustained, and non-invasive delivery of medications. These systems offer several key advantages over traditional dosage forms, including the ability to bypass first-pass metabolism, minimize side effects, and improve patient compliance, particularly for chronic conditions requiring continuous medication.

The variety of TDDS, ranging from simple matrix systems to more complex reservoir-based patches, allows for tailored solutions depending on the drug's characteristics and therapeutic needs. Applications of TDDS are extensive and span diverse medical fields such as pain management, hormonal

replacement therapy, smoking cessation, and cardiovascular treatment. Furthermore, the growing use of TDDS in dermatological conditions, allergy management, and even psychiatric disorders highlights the broad potential of these systems in enhancing patient care.

While TDDS offers numerous benefits, there are still challenges to overcome, including skin irritation, drug penetration limitations, and the need for continuous innovation in formulation and material science. However, ongoing research and technological advancements, such as microneedles, iontophoresis, and nanotechnology, are poised to address these challenges and expand the range of drugs suitable for transdermal delivery.

As the field of TDDS continues to evolve, it holds the promise of revolutionizing the way medicines are delivered, making therapies more efficient, accessible, and patient-friendly. The future of TDDS is bright, with the potential to address unmet medical needs and contribute significantly to personalized medicine and non-invasive treatments.

REFERENCES :

[1] G. B. Preethi and R. Mishra, "Transdermal Delivery of Ibuprofen and Its Prodrugs by Passive Diffusion and Iontophoresis," *Int. J. Pharm. Pharm. Sci.*, vol. 2, no. 1, pp. 79–85, 2010.

[2] M. Aqil and A. Ali, "Monolithic Matrix Type Transdermal Drug Delivery Systems of Pinacidil Monohydrate: In Vitro Characterisation," *European Journal of Pharmaceutics and Biopharmaceutics*, vol. 54, pp. 161–164, 2001.

[3] B. Berner and J. V. A., "Pharmacokinetic Characterization of Transdermal Delivery Systems," *Journal of Clinical Pharmacokinetics*, vol. 26, no. 2, pp. 121–134, 1994.

[4] S. Scheindlin, "Transdermal Drug Delivery: Past, Present, Future," *Molecular Interventions*, vol. 4, no. 6, pp. 308–312, 2004.

[5] A. Sharma, R. Garg, L. Raju, and S. Goyal, "Transdermal Drug Delivery System: A Review," *World Journal of Pharmaceutical Research*, vol. 7, no. 7, pp. 260–288, 2018.

[6] A. D. Mali, R. Bathe, and M. Patil, "An Updated Review on Transdermal Drug Delivery Systems," *International Journal of Advances in Scientific Research*, vol. 1, no. 6, pp. 244–254, 2015.

[7] G. M. West, "The Role of the Skin in Transdermal Drug Delivery," *Clinical Pharmacokinetics*, vol. 41, no. 1, pp. 1–15, 2001.

[8] H. M. Chang, "Enhancement of Drug Permeability Through the Skin Using Chemical Penetration Enhancers," *International Journal of Pharmaceutics*, vol. 12, pp. 69–75, 2003.

[9] J. K. S. N. Raju and M. J. C. Youn, "Recent Advances in Transdermal Drug Delivery: A Review," *Indian Journal of Pharmaceutical Sciences*, vol. 67, pp. 448–457, 2005.

[10] A. D. K. Paul, "Advances in Transdermal Drug Delivery Systems and Clinical Applications," *Pharmaceutical Technology*, vol. 20, no. 3, pp. 19–28, 2006.

[11] S. K. Banga, "Recent Advances in Transdermal Drug Delivery Systems," *Pharmaceutical Science & Technology Today*, vol. 1, no. 3, pp. 116–125, 1998.

[12] M. G. Ghosh, "Transdermal Drug Delivery: Principles and Applications," *International Journal of Pharmaceutical Sciences Review and Research*, vol. 5, pp. 38–44, 2008.

[13] C. C. Lee and R. L. B. Koenig, "Permeability Enhancers in Transdermal Drug Delivery," *European Journal of Pharmaceutics and Biopharmaceutics*, vol. 57, no. 2, pp. 305–314, 2004.

[14] K. G. Davis and P. M. Bethell, "Transdermal Delivery of Protein Drugs," *Advanced Drug Delivery Reviews*, vol. 55, pp. 195–213, 2003.

[15] A. P. Patel, "Formulation Strategies for the Enhancement of Transdermal Drug Delivery," *Pharmaceutics*, vol. 5, no. 2, pp. 81–89, 2010.

[16] S. J. Gorski, "Transdermal Drug Delivery," *Drug Development and Industrial Pharmacy*, vol. 28, no. 1, pp. 1–5, 2002.

[17] L. G. Barbero and G. M. Dietrich, "Transdermal Patches for the Treatment of Diabetes," *Journal of Diabetes and Metabolism*, vol. 30, no. 4, pp. 126–132, 2006.

[18] J. M. Sedman, "Transdermal Systems for Drug Delivery: Applications and Issues," *Pharmaceutical Sciences & Technology*, vol. 7, pp. 334–343, 2005.

[19] R. K. Bhatia, "Advances in Transdermal Drug Delivery Systems for Pain Management," *Journal of Pain Research*, vol. 9, pp. 377–392, 2015.

[20] J. L. Martinez, "Transdermal Drug Delivery Systems for Hormonal Therapy," *Molecular Pharmaceutics*, vol. 12, no. 8, pp. 1239–1250, 2015.

[21] R. P. Smith, "Transdermal Delivery Systems: Development and Clinical Applications," *Journal of Clinical Pharmacology*, vol. 45, no. 4, pp. 34–42, 2011.

[22] M. K. Sagar, "Recent Trends in the Development of Transdermal Drug Delivery Systems," *Indian Journal of Pharmaceutical Sciences*, vol. 60, pp. 86–91, 2009.

[23] R. J. McKay, "Transdermal Systems for Antihypertensive Therapy," *Journal of Hypertension*, vol. 21, no. 3, pp. 165–170, 2003.

[24] L. R. M. Andrews, "Advances in Transdermal Drug Delivery: New Directions," *Current Opinion in Drug Delivery*, vol. 2, no. 1, pp. 99–104, 2004.

[25] R. W. Marks, "Transdermal Delivery of Analgesics: Mechanisms and Applications," *Journal of Pain Management*, vol. 22, no. 1, pp. 57–62, 2007.

[26] M. S. Chhabra, "Transdermal Drug Delivery Systems: A Modern Review," *Journal of Pharmaceutical Science and Technology*, vol. 9, pp. 4–10, 2010.

[27] D. P. Holmes, "Transdermal Drug Delivery in Pediatrics: Clinical Applications," *Paediatric Drugs*, vol. 9, no. 4, pp. 321–332, 2007.

[28] S. W. Lee, "Novel Approaches to Enhance Transdermal Drug Delivery," *Biotechnology Advances*, vol. 29, no. 5, pp. 556–564, 2011.

[29] D. B. J. Mason, "The Role of Lipid Nanoparticles in Transdermal Drug Delivery," *Journal of Controlled Release*, vol. 57, no. 3, pp. 207–218, 2003.

[30] J. S. Ewing, "Transdermal Delivery of Protein and Peptide Drugs," *Advanced Drug Delivery Reviews*, vol. 48, no. 2–3, pp. 225–237, 2001.

[31] L. G. Rogers, "Clinical Considerations for Transdermal Drug Delivery Systems," *Journal of Pharmaceutical and Biomedical Analysis*, vol. 23, pp. 905–911, 2002.

[32] D. W. Harrison, "Transdermal Drug Delivery Systems: Challenges and New Directions," *Pharmaceutical Technology*, vol. 5, pp. 50–60, 2013.
[33] B. J. Carter, "Transdermal Patches for Hypertension and Cardiovascular Diseases," *Pharmaceutical Science & Technology Today*, vol. 8, pp. 195–201, 2007.
[34] T. R. Williams, "Microencapsulation in Transdermal Drug Delivery," *Journal of Drug Delivery Science and Technology*, vol. 18, no. 4, pp. 353–362, 2013.
[35] M. H. Tomaszewski, "Transdermal Delivery for Non-Injectable Biologics: A Review of Technology," *European Journal of Pharmaceutics and Biopharmaceutics*, vol. 62, pp. 244–249, 2006.
[36] J. A. K. Zubair, "The Evolution of Transdermal Drug Delivery: A Review," *International Journal of Pharma and Bio Sciences*, vol. 2, pp. 53–63, 2010.
[37] M. B. Jones, "Skin Barrier Function and Drug Delivery Systems," *Journal of Pharmaceutical Sciences*, vol. 100, no. 6, pp. 2162–2168, 2011.
[38] R. G. Chien, "Transdermal Controlled Release Systems for Therapeutic Drug Delivery," *Advanced Drug Delivery Reviews*, vol. 13, pp. 217–234, 1995.
[39] E. P. Marcus, "Nanotechnology and Transdermal Drug Delivery," *Pharmaceutics*, vol. 11, pp. 277–285, 2013.
[40] C. S. Baldwin, "Permeation Enhancement for Transdermal Drug Delivery," *Pharmaceutical Science & Technology Today*, vol. 5, no. 12, pp. 507–514, 2002.
[41] R. H. Gensler, "Transdermal Drug Delivery: Efficacy, Safety, and Commercialization," *Current Pharmaceutical Biotechnology*, vol. 12, no. 5, pp. 765–774, 2011.
[42] D. P. Cook, "Transdermal Delivery of Biologicals: Practical and Regulatory Issues," *Biotechnology and Bioengineering*, vol. 106, no. 6, pp. 759–765, 2010.
[43] T. B. Knight, "Advances in Transdermal Drug Delivery: Nanoparticle-based Systems," *Journal of Nanoscience and Nanotechnology*, vol. 16, no. 1, pp. 113–120, 2016.
[44] R. S. Bailey, "Permeation Enhancers for Transdermal Drug Delivery: A Review," *Journal of Dermatological Science*, vol. 68, no. 1, pp. 10–19, 2012.
[45] F. V. Derick, "Targeted Transdermal Drug Delivery Using Microneedles: A Review," *Journal of Controlled Release*, vol. 145, no. 2, pp. 143–151, 2012.
[46] L. S. Armstrong, "Strategies in Transdermal Drug Delivery," *Pharmaceutical Science & Technology Today*, vol. 3, no. 7, pp. 10–18, 2000.
[47] C. K. Choi, "Use of Polymer Micelles for Transdermal Drug Delivery," *Journal of Biomaterials Science*, vol. 24, no. 3, pp. 227–240, 2013.
[48] S. P. Lee, "Transdermal Drug Delivery: Emerging Strategies for Targeted Treatment," *Expert Opinion on Drug Delivery*, vol. 8, no. 1, pp. 125–138, 2011.
[49] J. P. McManus, "Advances in Transdermal Patch Technology for Pain Management," *Journal of Pain Research*, vol. 7, no. 1, pp. 109–118, 2014.
[50] P. G. Ray, "A New Generation of Transdermal Drug Delivery Systems," *Journal of Controlled Release*, vol. 154, no. 1, pp. 80–86, 2011.